ePT--the Electronic Newsletter of Pharmaceutical Technology
Argonne, IL (Nov. 9)-Researchers from Argonne National Laboratory?s Chemistry Division and Xradia have developed a novel X-ray microscopy technique that allows molecular observations of the reactivity of solid surfaces at the nanometer scale, including interfacial reactions such as ion adsorption and catalytic reactions.
Argonne, IL (Nov. 9)-Researchers from Argonne National Laboratory’s Chemistry Division (www.anl.gov) and Xradia (Concord, CA, www.xradia.com) have developed a novel X-ray microscopy technique that allows molecular observations of the reactivity of solid surfaces at the nanometer scale, including interfacial reactions such as ion adsorption and catalytic reactions.
Combining X-ray reflection and high-resolution microscopy, the non-invasive method also permits scientists to observe sub-nanometer-sized interfacial features in real time and image the topography of a solid surface without the need for probe tips near the surface.
The technique implements the concepts of phase contrast microscopy, which allows colorless specimens or finely detailed organisms to appear more clearly at high magnifications by retarding the phase of highly reflective light from objects, such as granules, with a high refractive index. This correction is not performed with commonly used microscopy methods such as bright-field microscopy.
Funding for the research was provided by the US Department of Energy’s Office of Basic Energy Sciences, and results were published in Nature Physics (2006).
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.